The articles listed on this page are from a variety of sources. 
1. The staff of DBS-STN often attends conferences or educational opportunities both nationally and internationally, and a brief understandable write-up of the information presented at the event will be provided for our readers to review. 
2. DBS-STN staff also identifies or writes various articles related to topics that are thought to be of interest for the reader of www.DBS-STN.org. 

Browse by Topic:
Search:

Biotie Provides Update on Tozadenant


(February 26, 2015) - Biotie announces further detail on its clinical development plan for tozadenant, an adenosine A2a antagonist in development for treatment of Parkinson's disease (PD). The primary endpoint of Biotie’s Phase 3 study of PD patients experiencing levodopa related end-of-dose 'wearing-off' (motor fluctuations) will be time spent in the "off" state in patients taking tozadenant versus a placebo. Based on current estimates, top-line data is expected to be available by the end of 2018. Read more…



Article Archive

back